AKT1 and hepatocellular carcinoma: The data concerning Akt inhibitors in HCC are still preliminary and future clinical development may have to involve combinations with other targeted therapies such as β-catenin inhibitors or immune checkpoint inhibitors to improve the care of HCC patients.